drugset / Trial / NCT00769860
Arimoclomol in Sporadic Inclusion Body Myositis
RandomizedParallel-groupDouble-blindTreatment
Summary
Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment.
Timeline
- Start
- 2008-09
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Arimoclomol | Small molecule | 100 mg | — |